Rome Sandra, Doss Deborah, Miller Kena, Westphal Jeanne
Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):21-8. doi: 10.1188/08.CJON.S1.21-27.
Patients with myeloma are at risk for serious and life-threatening thromboembolic events because of their disease, individual risk factors, and antimyeloma or other medications. The International Myeloma Foundation's Nurse Leadership Board developed this consensus statement for assessment and prevention of thromboembolic events. Prophylactic measures are categorized as mechanical, regimen related, and antithrombotic drug, based on individual and myeloma-related risk factors. Aspirin is suggested for patients with no or one risk factor, low-molecular-weight heparin or full-dose warfarin for patients with two or more risk factors, and low-molecular-weight heparin or full-dose warfarin for all patients with therapy-related risks, including high-dose dexamethasone, doxorubicin, or multiagent chemotherapy.
